Ardelyx has revealed that its small molecule, non-binder, phosphate absorption inhibitor tenapanor met all primary and key secondary endpoints at Phase 3 when used in combination with phosphate binders in the treatment of patients with chronic kidney disease (CKD) on dialysis whose hyperphosphatemia was not previously controlled with binders alone.
The data showed that, in the trial population of 236 patients, the combo produced a statistically significant mean reduction in serum phosphorus levels from baseline of 0.84mg/dL, compared to 0.19mg/dL for phosphate binders alone.
